Citius Pharmaceuticals Inc (CTXR) Stock Analysis
Verdict: AVOID
Severe liquidity crunch and consistent earnings misses overshadow pipeline potential, requiring immediate dilutive financing to survive.
Investment score: 28/100
Analysis as of
Is Citius Pharmaceuticals Inc stock worth reviewing? AI model thesis
CTXR is facing a critical capital shortfall with less than one year of runway and a deteriorating technical profile following a major earnings miss.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Citius Pharmaceuticals Inc opportunities and risks
What speaks for CTXR
- FDA Approval for Mino-Lok
What speaks against CTXR
- Imminent Dilutive Financing
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CTXR | n/a | 0.9x | 0.1x | 44.2% | -694.3% | -502.5% |
| TVRD | n/a | 0.0x | n/a | 0.0% | 0.0% | -138.2% |
| LPCN | n/a | 11.0x | n/a | 98.1% | -755.1% | -64.9% |
| PRTT | 2.5x | 0.7x | 0.2x | 55.7% | 25.2% | -15.4% |
| HIND | n/a | 120.7x | n/a | 46.5% | -8716.8% | -33.6% |
| Peer median | n/a | 5.8x | n/a | 51.1% | -377.6% | -49.3% |
Frequently asked questions about Citius Pharmaceuticals Inc (CTXR)
Is CTXR stock a good investment?
The cached TradeMates AI model rates Citius Pharmaceuticals Inc as AVOID with an investment score of 28/100. CTXR is facing a critical capital shortfall with less than one year of runway and a deteriorating technical profile following a major earnings miss. This is algorithmic model output, not personal investment advice.
Is CTXR stock a buy?
The TradeMates model verdict for CTXR is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.